Recombinant Human Thyrotropin-Stimulated Radioiodine Therapy in Patients with Multinodular Goiters: A Meta-Analysis of Randomized Controlled Trials

Abstract

A potential reduction of goiter volume (GV) of recombinant human thyrotropin (rhTSH) on multinodular goiters (MNG) was previously reported but controversial. Hence we conducted a meta-analysis to estimate the effect of rhTSH-stimulated radioiodine therapy in patients with MNG. PubMed, Cochrane, CNKI, VIP, and Wanfang databases were searched. Mean difference (MD) and odds ratios with 95% confidence intervals (95% CI) were derived by using an inverse variance random-effects model and fixed-effects model, respectively. Six studies (n=237) were involved in the analysis. For 12 months follow up, high dose (>0.1 mg) of rhTSH significantly reduced GV (MD=17.61; 95% CI=12.17 to 23.04; p<0.00001) compared with placebo. No effective pooled results of low dose of rhTSH (<0.1 mg) were applicable for only one study included. For 6 months follow up, the source of heterogeneity was determined by subgroup and sensitivity analysis. High dose group showed vast improvement in GV reduction (MD=16.62; 95% CI=1.34 to 31.90; p=0.03). The reduction of low dose group compared with placebo was inferior to high dose group. No available data were obtained to assess the influence of rhTSH after 36 months follow up for the only included study. Hypothyroidism incidence was higher for rhTSH group. No publication bias was seen. High dose of rhTSH treatment-stimulated radioactive ¹³¹I therapy after 6 months and 12 months follow up had a better effect in reducing GV, but with higher incidence of hypothyroidism. Owing to the limited methodological quality, more clinical researches are warranted in the future.

Key words

multinodular goiters - recombinant human thyrotropin - radioiodine therapy - meta-analysis

^# Co-first authors.

Publikationsverlauf

Eingereicht: 05. Mai 2020

Angenommen nach Revision: 07. August 2020

Artikel online veröffentlicht:
22. September 2020

• References

• 1 Knobel M. Etiopathology, clinical features, and treatment of diffuse and multinodular nontoxic goiters. J Endocrinol Invest 2016; 39: 357-373
• 2 Bandeira-Echtler E, Bergerhoff K, Richter B. Levothyroxine or minimally invasive therapies for benign thyroid nodules. Cochrane Database Syst Rev 2014; 18: CD004098
• 3 Dogan L, Karaman N, Yilmaz KB. et al. Total thyroidectomy for the surgical treatment of multinodular goiter. Surg Today 2011; 41: 323-327
• 4 Gharib H, Papini E, Paschke R. et al. AACE/AME/ETA Task Force on Thyroid Nodules of the American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association medical guidelines for clinical practice for the diagnosis and management of thyroid nodules: Executive summary of recommendations. Endocr Pract 2010; 16 (Suppl. 01) 468-475
• 5 American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer Cooper DS, Doherty GM. et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19: 1167-1214
• 6 Sorensen JR. The impact of surgery on quality of life, esophageal motility, and tracheal anatomy and airflow in patients with benign nodular goiter. Dan Med J 2018; 65: B5472
• 7 Braverman L, Kloos RT, Law B. et al. Evaluation of various doses of recombinant human thyrotropin in patients with multinodular goiters. Endocr Pract 2008; 14: 832-839
• 8 Medeiros-Neto G. Multinodular Goiter. In: Feingold KR, Eds.Endotext [Internet] South Dartmouth MDText.com, Inc.; 2000
• 9 Bonnema SJ, Fast S, Hegedüs L. Non-surgical approach to the benign nodular goiter: New opportunities by recombinant human TSH-stimulated 131I-therapy. Endocrine 2011; 40: 344-353
• 10 Ceccarelli C, Antonangeli L, Brozzi F. et al. Radioiodine 131I treatment for large nodular goiter: recombinant human thyrotropin allows the reduction of radioiodine 131I activity to be administered in patients with low uptake. Thyroid 2011; 21: 759-764
• 11 Mojsak MN, Abdelrazek S, Szumowski P. et al. Single, very low dose (0.03 mg) of recombinant human thyrotropin (rhTSH) effectively increases radioiodine uptake in the I-131 treatment of large nontoxic multinodular goiter. Nucl Med Rev 2016; 19: 3-11
• 12 Azorín Belda MJ, Martínez Caballero A, Figueroa Ardila GC. et al. Recombinant human thyrotropin stimulation prior to 131I therapy in toxic multinodular goiter with low radioactive iodine uptake. Rev Esp Med Nucl Ima 2017; 36: 7-12
• 13 Albino CC, Graf H, Paz-Filho G. et al. Radioiodine plus recombinant human thyrotropin do not cause acute airway compression and are effective in reducing multinodular goiter. Braz J Med Biol Res 2010; 43: 303-309
• 14 Silva MN, Rubió IG, Romão R. et al. Administration of a single dose of recombinant human thyrotrophin enhances the efficacy of radioiodine treatment of large compressive multinodular goiters. Clin Endocrinol 2004; 60: 300-308
• 15 Graf H, Fast S, Pacini F. et al. Modified-Release Recombinant Human TSH (MRrhTSH) augments the effect of 131I therapy in benign multinodular goiter: results from a multicenter international, randomized, placebo-controlled study. J Clin Endocrinol Metab 2011; 96: 1368-1376
• 16 Nielsen VE, Bonnema SJ, Boel-Jørgensen H. et al. Stimulation with 0.3-mg recombinant human thyrotropin prior to iodine 131 therapy to improve the size reduction of benign nontoxic nodular goiter: A prospective randomized double-blind trial. Arch Intern Med 2006; 66: 1476-1482
• 17 Bonnema SJ, Nielsen VE, Boel-Jørgensen H. et al. Improvement of goiter volume reduction after 0.3 mg recombinant human thyrotropin-stimulated radioiodine therapy in patients with a very large goiter: A double-blinded, randomized trial. J Clin Endocrinol Metab 2007; 92: 3424-3428
• 18 Fast S, Hegedüs L, Pacini F. et al. Long-term efficacy of modified-release recombinant human thyrotropin augmented radioiodine therapy for benign multinodular goiter: Results from a multicenter, international, randomized, placebo-controlled, dose-selection study. Thyroid 2014; 24: 727-735
• 19 Bonnema SJ, Nielsen VE, Boel-Jørgensen H. et al. Recombinant human thyrotropin-stimulated radioiodine therapy of large nodular goiters facilitates tracheal decompression and improves inspiration. J Clin Endocr Metab 2008; 93: 3981-3984
• 20 Jasim S, Gharib H. Multinodular Goiter. In: Gharib H, Ed. Thyroid Nodules. Contemporary Endocrinology. Cham: Humana Press; 2018: 135-152
• 21 Charalambous A. Seeking optimal management for radioactive iodine therapy-induced adverse effects. Asia Pac J Oncol Nurs 2017; 4: 319-322
• 22 Fast S, Nielsen VE, Bonnema SJ. et al. Time to reconsider nonsurgical therapy of benign non-toxic multinodular goitre: Focus on recombinant human TSH augmented radioiodine therapy. Eur J Endocrinol 2009; 160: 517-528
• 23 Nguyen QT, Lee EJ, Huang MG. et al. Diagnosis and treatment of patients with thyroid cancer. Am Health Drug Benefits 2015; 8: 30-40
• 24 Haugen BR, Alexander EK, Bible KC. et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016: 1-133
• 25 Bonnema SJ, Hegedus L. Nontoxic Goiter. In: Vitti P, Hegedus L, Eds. Thyroid Diseases. Endocrinology. Cham: Springer; 2017: 1-38
• 26 Giusti M, Caorsi V, Mortara L. et al. Long-term outcome after radioiodine therapy with adjuvant rhTSH treatment: comparison between patients with non-toxic and pre-toxic large multinodular goitre. Endocrine 2014; 45: 221-229
• 27 Bonnema SJ, Hegedüs L. Radioiodine Therapy in Benign Thyroid Diseases: Effects, side effects, and factors affecting therapeutic outcome. Endocr Rev 2012; 33: 920-980
• 28 Sheehan MT, Doi SA. Transient hypothyroidism after radioiodine for Graves’ disease: Challenges in interpreting thyroid function tests. Clin Med Res 2016; 14: 40-45